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Abstract
Paclitaxel (Pac) is an antitumor agent that is widely used for treatment of solid cancers. While being effective as a
chemotherapeutic agent, Pac in high doses is neurotoxic, specifically targeting sensory innervations. In view of these toxic
effects associated with conventional chemotherapy, decreasing the dose of Pac has been recently suggested as an
alternative approach, which might limit neurotoxicity and immunosuppression. However, it remains unclear if low doses of
Pac retain its neurotoxic properties or might exhibit unusual effects on neuronal cells. The goal of this study was to analyze
the concentration-dependent effect of Pac on isolated and cultured DRG neuronal cells from wild-type and TLR4 knockout
mice. Three different morphological parameters were analyzed: the number of neurons which developed neurites, the
number of neurites per cell and the total length of neurites per cell. Our data demonstrate that low concentrations of Pac
(0.1 nM and 0.5 nM) do not influence the neuronal growth in cultures in both wild type and TLR4 knockout mice. Higher
concentrations of Pac (1–100 nM) had a significant effect on DRG neurons from wild type mice, affecting the number of
neurons which developed neurites, number of neurites per cell, and the length of neurites. In DRG from TLR4 knockout mice
high concentrations of Pac showed a similar effect on the number of neurons which developed neurites and the length of
neurites. At the same time, the number of neurites per cell, indicating the process of growth cone initiation, was not
affected by high concentrations of Pac. Thus, our data showed that Pac in high concentrations has a significant damaging
effect on axonal growth and that this effect is partially mediated through TLR4 pathways. Low doses of Pac are devoid of
neuronal toxicity and thus can be safely used in a chemomodulation mode.
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Introduction
Paclitaxel (Pac), a diterpene purified from the bark of the
western Yew (Taxus brevifolia), is an antitumor agent that is widely
used for treatment of breast, lung and other solid cancers [1,2,3].
Pac primarily exerts its effect by binding to the b-tubulin subunit
in microtubules, preventing depolymerization and increasing their
stability and rigidity. This leads to enhanced polymerization, cell-
cycle arrest and enhanced apoptosis of proliferating cells [4]. In
addition, Pac was shown to be a ligand to TLR4, a member of the
Toll-like receptor family, a class of pattern recognition molecules
in innate and acquired immune responses [5]. Expression of
TLR4 was also detected in several tumors and tumor cell lines and
was shown to be involved in the anti-proliferative action of Pac [6].
Recently TLR4 was found to be expressed on central and
peripheral neurons [7,8,9]; however, the functional impact of
TLR4 signaling in neurons remains to be determined. TLR4-
deficient mice demonstrated enhanced neural stem/progenitor cell
proliferation and neuronal differentiation [10]. In addition, TLR4-
deficient mice displayed increases in diffuse amyloid beta-protein
and its deposits compared with WT mice [11], suggesting that
TLR4 signaling might be involved in Alzheimer’s disease
progression and could be a new therapeutic target for Alzheimer’s
disease [12].
While being effective as a chemotherapeutic agent, Pac in high
therapeutic doses (MTD, maximum tolerated doses) has several
significant side effects. Peripheral neuropathy is the major adverse
effect associated with the therapeutic use of Pac and this has been
demonstrated to be dependent upon the dose administered, the
duration of the infusion, and the schedule of administration. The
symptoms of sensory loss and paresthesia can persist even
following cessation of treatment with Pac and may significantly
impact on quality of life of patients with cancer [13,14]. The
development of neuropathy is dose-dependent and appears to be
more prevalent with dose-dense regiments. The symptoms often
occur in anatomical structures innervated by the longest nerves in
a symmetrical manner predominantly affecting the distal hands
and feet [15]. This suggests that Pac may target the cell bodies of
sensory neurons. In fact, preferential accumulation of Pac has
been reported in the dorsal root ganglia (DRGs) following
intravenous administration in rodents [16]. In-vivo studies have
suggested that Pac produces neurotoxicity via interruption of
microtubule dynamics leading to overstabilization and subsequent
axonal transport dysfunction [17]. With prolonged dysfunction,
chronic Pac administration may eventually lead to axonal
degeneration via multiple mechanisms, including calcium-medi-
ated calpain cascade activation, mitochondrial dysfunction, and
long-term effects of axonal transport deficits [14].
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Although the use of Pac as a chemotherapeutic agent has
become a broadly accepted option in the treatment of patients
with different solid tumors, significant toxicities, such as peripheral
neuropathy and myelosuppression, limit the effectiveness of Pac-
based treatment regimens. MTD-based Pac chemotherapy can
efficiently suppress the generation and function of the immune
cells leading to increased susceptibility to infectious diseases and
collapse of the anti-tumor immunity [18,19,20]. In view of these
undesirable toxic effects associated with conventional chemother-
apy, decreasing the dose of Pac has been recently suggested as an
alternative approach, which might limit neurotoxicity and
immunosuppression [21]. For instance, it has been recently
reported that Pac in low and ultra low doses directly stimulates
activity of immune effector cells, increases their ability to recognize
cancerous cells [22,23], and up-regulates the efficacy of anticancer
immunotherapy in vivo [24]. Interestingly, Pac in ultra low doses
may also decrease the number and activity of immunosuppressive
immune regulatory cells both in vivo and in vitro [25,26]. This
new phenomenon, i.e., immunostimulatory properties of certain
chemotherapeutic agents in ultra low doses, has been called
‘chemomodulation’ [21,27,28] and suggests that certain chemo-
therapeutic drugs, including Pac, may exhibit unexpected
noncytotoxic/noncytostatic activities when used in ultra low
doses. However, it remains unclear if low and ultra low doses of
Pac retain its neurotoxic properties or might exhibit unusual
effects on neuronal cells.
The goal of this study was to analyze the dose-dependent effects
of Pac on neuronal cells in a mouse DRG model in vitro and its
dependability on TLR4 signaling. We have demonstrated a
marked negative effect of high concentrations of Pac on neurite
growth, which was partially mediated by the TLR4 signaling. In




Six- to eight-week-old male C57BL/6 mice (Taconic, German-
town, NY) and C57BL/10ScNJ mice with a deletion of the Tlr4
gene (Jackson Lab, Bar Harbor, Maine) were housed in a
pathogen-free facility under controlled temperature, humidity,
and 12-h light/dark cycle with a commercial rodent diet and water
available ad libitum. Experimental protocols were approved by
University of Pittsburgh Institutional Animal Care and Use
Committees.
DRG cultures
DRG dissection and separation was performed according to
Malin et al. (2007) with small modifications [29]. Briefly, the mice
were sacrificed by carbon dioxide inhalation and DRG ganglions
were dissected immediately from the spinal column and collected
in Ca++/Mg++- free HBSS (Invitrogen, Grand Island, NY).
Ganglia were incubated at 37uC with 60 units of papain for
10 min followed by 20 min incubation with the mixture of 4 mg/
ml collagenase-2 and 4.5 mg/ml neutral peptidase (all from
Worthington Biochemical Corporation, Lakewood, NJ). Enzymat-
ically dissociated ganglia were washed in F-15 medium (Invitro-
gen, Grand Island, NY) and gently triturated by a series of
pipetting with decreasing tip diameter. Dissociated neurons were
resuspended in F-15 medium containing 10% heat-inactivated
FCS and 1% penicillin/streptomycin (10,000 U/ml). Cell suspen-
sion (150 ml) was distributed on rounded glass coverslips pre-
coated with poly-d-lysine (10 mg/ml)/laminin (200 mg/ml) (all
from Sigma-Aldrich, St. Louis, MO) and placed in 12-well culture
plates. Two hours later all wells were filled with additional 850 ml
of complete F-15 medium. Pac (Mayne Pharma, Salisbury South,
Australia) was added to neuronal cultures at final concentrations of
0.1 nM–100 nM.
Neurons were cultured for 48 hours at 37uC in 5% CO2. At
24 hours, 75% of culture medium was replaced with the fresh
medium containing the same concentrations of Pac. Forty-eight
hours after plating, coverslips with cultured neurons were fixed in
2% paraformaldehyde, stained with brilliant blue stain (Sigma)
and mounted on the glass slides.
In separate series of experiments we evaluated the effects of
TLR4 inhibitor [30] and TLR4 agonist, lipopolysaccharide (LPS)
on the neurons from wild type animals, treated and untreated with
PAC. LPS-RS Ultrapure (5 mg/ml) (InvivoGen, San Diego, CA),
LPS (0.5 mg/ml) (Sigma-Aldrich, St Louis, MO) and PAC
(100 nM) were added to the neuron media 2 hours after plating,
as described above.
Cytotoxicity Assay
Effect of Pac on the viability of neuronal cells was tested using
aCella-Tox kit (Cell Technology, Mountain View, CA). Briefly,
the cells were plated at 2000 cells per well and treated with PAC as
described above. After 48 hours 100 ml of supernatant was
collected from the well and transferred to the white opaque 96
well plate in triplicates. Then, 10 ml of lytic agent was added to the
cells for 15 min and another 100 ml sample (positive control–total
lysis) was also transferred to the 96 well plate. 100 ml of Enzyme
Assay Reagent containing Gyceraldehyde 3-Phosphate was then
added to all wells followed by 50 ml of the detection reagent. The
plate was immediately read using luminometer (Synergy HT,




Analysis of neurite growth
Slides were prepared in triplicates for all tested concentrations
of Pac. Twelve randomly selected fields on each slide were
photographed at 400X magnification. Images were analyzed with
the ImageJ software package (Rasband WS, ImageJ, NIH, http://
imagej.nih.gov/ij). Neurites were traced and their lengths were
measured with NeuronJ plugin [31]. Cell process exceeding 2
body lengths was considered a neurite. The percentage of DRG
neurons with neurites, total length of neurites, and the number of
neurites per cell were calculated for each field by two investigators,
blinded to the neuron treatment. No less than 40 cells were
analyzed per slide, with the average of 1030 cells per slide.
Statistical analysis
Statistical evaluation of the difference in the number of neurons
developing neurites, neurite lengths and the number of neurites
per cell was performed using the GraphPad Prism statistical
software (GraphPad Software, San Diego, CA). For all analyses,
the level of significance was set at probability of p,0.05. ANOVA
was used for comparison of multiple groups. For single comparison
of two groups, the Student t-test was used after evaluation of
normality. All experiments were repeated at least 3–4 times. Data
are presented as the means 6 SEM.
TLR4 in Paclitaxel Effects on Neurons In Vitro
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Results
Effect of paclitaxel on neuron viability
Pac in the concentrations 0.1–100 nM had no effect on the
neuron viability. The percent of neuronal death after 48 hours in
culture was 1263% in the absence of Pac and 1664% at the
highest concentration of paclitaxel of 100 nM.
Concentration-dependent effects of paclitaxel on
cultured neurons
Three different morphological parameters were analyzed in
each slide: the number of neurons which developed neurites, the
number of neurites per cell and the total length of neurites per cell.
The first two of these parameters reflect the process of growth cone
initiation and the third one reveals the process of neurite
extension.
As expected, immediately after harvesting and plating the
neurons appear as round cells with no neurites. After 24 hours in
Pac-free cultures, the process of neurite development was initiated.
At 48 hours, the vast majority of cultured neurons (70.863.5%)
have numerous well defined neurites with an extensive branching
(Figure 1). The average length of neurites per cell was
10956115 mm.
In DRG neurons isolated from wild type animals, Pac in low
concentrations (0.1 nM and 0.5 nM) affected neither the number
of regenerating neurons nor the total number and length of
neurites per cell (p.0.05). In contrast, high concentrations of Pac
showed a significant concentration-dependent inhibition of neurite
growth by decreasing the number of regenerating neurons, the
number of neurites per cell, and the total length of neurites.
Morphologically, neurons develop numerous short processes, only
few of which continue to grow and present as well-formed neurites.
Specifically, at the concentration of 1 nM only 53.266.1% of
neurons developed neurites (p,0.05 vs control), and at the high
concentrations of 10 nM and 100 nM only one third of neurons
had neurites (28.564.3%, p,0.05 vs control) (Figure 2). The
number of neurites per cell was lower at concentrations of 1 nM–
100 nM (Figure 3). For instance, in the absence of Pac neurons
developed 3.060.2 neurites per cell and at the concentration of
1 nM and 100 nM of Pac only 2.360.1 and 2.160.1 neurites per
cell, respectively (p,0.01). The average length of neurites per cell
was significantly decreased at the high concentrations of 10 nM
and 100 nM, but was not affected at the concentration of 1 nM
(Figure 4). For example, at the concentration of 1 nM the lengths
of neurites per cell was 9436112 mm vs.10966142 mm in the
absence of Pac (p = 0.1). At the concentration of 10 nM and
100 nM the lengths of neurites per cell was 368659 mm and
244623 mm, respectively (p,0.001).
Thus, these data demonstrate that in DRG neurons from wild
type animals Pac does not affect neuronal growth at low
concentrations (0.1–0.5 nM), but significantly decreases all
parameters of neuronal growth at the high concentrations of 10–
100 nM.
Figure 1. Cell morphology of neurons in DRG cultures (high
power view). A. In control cultures, neurons develop numerous well
defined neurites with multiple extensive branching after 48 h of
incubation. B. Neurons incubated with high concentrations of Pac
(100 nM) develop multiple short processes, but no well-formed
neurites. Representative pictures are shown from .5 independent
experiments with similar results.
doi:10.1371/journal.pone.0056886.g001
Figure 2. Effects of paclitaxel on the number of neurons with
neurites in control and treated DRG cultures. DRG cultures were
prepared from wild type and TLR4 knockout animals as described in
Materials and Methods. Pac was added to cultures at concentrations
0.1 nM–100 nM. As shown, Pac reduces the number of regenerating
neurons in a concentration-dependent manner, both in DRG cultures
obtained from control wild type (solid bars) and TLR4 knockout mice
(open bars). *, p,0.05 versus 0 M of Pac in the same group (N=5, one-
way ANOVA).
doi:10.1371/journal.pone.0056886.g002
Figure 3. Effects of paclitaxel on the number of neurites per
cell in control and treated DRG cultures. DRG cultures were
prepared from wild type and TLR4 knockout mice as described in
Materials and Methods. Pac was added to cultures at concentrations
0.1 nM–100 nM. Pac inhibits neurite development in a concentration-
dependent manner in wild type mice (solid bars), but not in TLR4
knockout mice (open bars). *, p,0.05 versus 0 M of Pac in the same
group; #, p,0.05 vs. wild type at the same concentration of Pac (N= 5,
one-way ANOVA).
doi:10.1371/journal.pone.0056886.g003
TLR4 in Paclitaxel Effects on Neurons In Vitro
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Effects of paclitaxel on neurons obtained from TLR4
knockout mice
As shown on Figure 2, in the absence of Pac neurons from
TLR4 knockout mice had approximately the same proportion of
cells that develop neurites as the neurons from wild type mice
(66.462.3% vs. 70.863.5%, p= 0.14). The number of neurites
per cell in Pac-free cultures also was not different from wild type
mice (2.760.2 vs 3.060.2, p = 0.14) (Figure 3). However, the
average length of neurites in Pac-free cultures from TLR4
knockout mice was significantly lower than in the cultures from
wild type mice (818663 mm vs.10966141 mm, p= 0.03) (Figure 4).
Low concentrations of Pac (0.1 nM and 0.5 nM) did not influence
the proportion of cells with neurites and the average length of
neurites in cultures obtained from TLR4-deficient mice. High
concentrations of Pac (10 nM and 100 nM) significantly decreased
the proportion of cells developing neurites (26.262.8% and
22.363.5%, respectively; p,0.05 vs 0 nM Pac) and the average
length of neurites (304636 mm and 312636 m, respectively;
p,0.05 vs 0 nM Pac) in the same manner as in the cultures from
wild type animals.
Interestingly, in contrast to wild type animals, Pac did not
influence the number of neurites per cell in cultures prepared from
TLR4-deficient mice even at the high concentrations. The
number of neurites per cell at the highest concentration of Pac
of 100 nM was 2.960.4 vs 2.760.1 in Pac-free medium. At the
concentrations of 10 nM and 100 nM neurons from the TLR4
knockout mice had significantly more neurites per cell than
neurons from wild-type animals at the same concentrations of Pac:
2.860.2 vs 2.360.2 (p,0.05) at 10 nM and 2.960.4 vs 2.160.1
(p,0.05) at 100 nM.
Effect of LPS-RS on paclitaxel-treated neurons
To further evaluate the role of TLR4 signaling in Pac-induced
inhibition of neurite growth we attempted to block its action by
using TLR4 inhibitor LPS-RS. As shown on Figure 5, TLR4
inhibitor does not influence the number of neurons with neurites,
or the length of neurites after Pac treatment. However, the
number of neurites per cell is significantly higher in LPS-RS group
after Pac treatment. These data show the protective effect of LPS-
RS on the process of growth cone initiation in Pac-treated
neurons. To confirm that LPS-RS exerts its action through TLR4
inhibition, we evaluated the effect of TLR4 agonist (LPS) on
cultured neurons. As shown on Figure 5, LPS decreases the
number of neurites per cell, but does not influence other
morphologic parameters. The effect of LPS is completely
abolished by LPS-RS.
Figure 4. Effects of paclitaxel on the total length of neurites
per cell in control and treated DRG cultures. DRG cultures were
prepared from wild type and TLR4 knockout animals as described in
Materials and Methods. Pac was added to cultures at concentrations
0.1 nM–100 nM. As shown, Pac decreases the length of neurites in a
concentration-dependent manner both in control (solid bars) and TLR4
knockout mice (open bars). *, p,0.05 versus 0 M of Pac in the same
group; #, p,0.05 versus wild type at the same concentration of Pac.
(N = 5, one-way ANOVA).
doi:10.1371/journal.pone.0056886.g004
Figure 5. Effect of TLR4 inhibitor LPS-RS on the morphological
parameters of control, paclitaxel-treated and LPS-treated
neurons. DRG cultures were prepared from wild type animals as
described in Materials and Methods. Pac was added to cultures at
100 nM; LPS at concentration of 0.5 mg/ml and LPS-RS at concentration
of 5 mg/ml. A, percent of neurons with neurites; B, number of neurites
per cell; C, total length of neurites per cell. *, p,0.05 versus no LPS-RS;
#, p,0.05 versus respective control group (N= 5, one-way ANOVA).
doi:10.1371/journal.pone.0056886.g005
TLR4 in Paclitaxel Effects on Neurons In Vitro
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In summary, our results revealed that Pac in low concentrations
did not affect the neuronal growth in DRG cultures prepared from
both wild type and TLR4 knockout mice. The effect of Pac at high
concentrations on the length of neurites did not depend on the
presence of TLR4, whereas the effect on the number of developing
cell processes was different in wild type and TLR4-deficient mice
suggesting the possible role of TRL4 signaling in neurite
development.
Discussion
Paclitaxel exerts its cellular effects through several different
mechanisms. The first one, which has been shown for numerous
cell types, consists of Pac binding to beta-tubulin [32]. This leads
to over-stabilization of microtubules and disruption of vital
functions such as cell division, maintenance of cell shape and
intracellular transport [33]. Another mechanism is an interaction
of Pac with TLR4 receptor, which produces different cellular
effect, depending on the type of cells involved [34,35]. Activation
of the TLR4 signaling by Pac has been demonstrated in murine
macrophages, transfected cell lines, and mouse tumor cell lines
[35,36], although the results revealing involvement of TLR4 on
the Pac effects on myeloid cells are controversial [19] and might be
concentration-dependent [28].
Paclitaxel is widely used in oncology clinic, but the therapeutic
concentrations are neurotoxic, specifically targeting sensory
innervations. Pac-induced neuropathy is characterized by prom-
inent paresthesias and dysesthesias with abnormal functions of
both large and small sensory fibers [13,37]. Sensory nerve
dysfunction is typically more common than motor involvement,
perhaps reflecting the vulnerability of sensory neuronal cell bodies
in the DRG to toxic damage. The prominent vascularization of
the DRG and permeability of the blood-nerve barrier may support
the accumulation of toxic compounds in sensory neurons [14].
One can assume that Pac causes neuronal damage through its two
known pathways, but our understanding of the mechanisms
behind the neurotoxic effects of Pac is incomplete. Adult
peripheral neurons do not proliferate, and thus, the anti-mitotic
activity of Pac would not be a damaging factor. However, the
maintenance of axonal integrity and function requires constant
remodeling that involves regulation of axonal microtubular
structures [38]. In microtubules, tubulins are polymerized at one
end and are depolymerized at the other end constantly.
Dissociated tubulins and formed microtubules exist in equilibrium.
This equilibrium is necessary for axonal transport [13]. Systemic
Pac exposure in vitro induces marked microtubule aggregation in
large myelinated axons and DRG neurons [39,40]. These data
indicate that the first mechanism of Pac activity, i.e., tubulin
binding, is an important factor of its neurotoxicity. This
mechanism is shared by other taxanes (docetaxel) and other types
of microtubule-stabilizing agents, like epothilones, peloruside, etc
[17,41]. On the other hand, the role of TLR4-mediated effects of
Pac on neurons has not yet been evaluated.
In this study we have demonstrated a direct effect of Pac on
adult somatic neurons in murine DRG cultures. DRG culture is an
accepted model for evaluation of potential toxicity of different
chemotherapeutic drugs [42,43,44]. Our results showed that high
concentrations of Pac caused a significant damage of DRG
neurons taken from wild type mice. All of the morphologic
parameters that have been evaluated were markedly affected,
including the number of viable neurons, number of neurites per
cell, and the length of neurites. These results are in agreement with
earlier studies performed on murine, rat, and chicken neuronal
cultures [42,43,44].
The length of neurites of DRG neurons from TLR4 knockout
mice was inhibited to a similar extent as for wild type neurons;
however, the number of neurites per cell, indicating the process of
growth cone initiation, was not affected by either low or high
concentrations of Pac. Thus, our data prove for the first time that
Pac in high concentrations exerts its noxious effect on neurons
through two different mechanisms: tubulin-binding and TLR4
signaling. Its tubulin targeting activity is likely to be responsible for
a prevention of neurite outgrowth and elongation. It was
demonstrated previously that the neurite growth depends on
polymerization and depolymerization of microtubules that is
directly affected by Pac [13]. On the other hand, Pac effect on a
process of growth cone initiation depends on TLR4 signaling,
since cells from TLR4 knockout mice were protected against it.
TLR4-stimulating activity can be unique to Pac, since other
microtubule-stabilizing compounds, such as peloruside, docetaxel,
and epothilone B do not show this effect in animal models [45].
Pac effect on growth cone initiation was also abolished in wild-type
animals with the use of LPS-RS. This substance exerts its effect
through binding to MD-2 co-receptor, thus blocking TLR4-
dependent signaling [30]. The role of TLR receptors in neuronal
development is not clear, however, experimental data demonstrate
that signaling through TLR might causes growth cone collapse in
central and peripheral neurons in mice [46].
We have also shown that Pac in low and ultra-low concentra-
tions does not affect neuronal morphology and neurite growth.
Although these results are expected, they have a direct practical
significance, since low-dose chemotherapy finds its way into
clinical practice. A new therapeutic approach, called chemomo-
dulation, is based on an ability of certain chemotherapeutic agents,
including Pac, to enhance tumor immunogenicity without
inducing tumor cell apoptosis, and thus enhance the efficacy of
immunotherapy. Recently, we and others have shown that Pac in
low noncytotoxic doses exhibits multiple immunomodulating
activities, including tumor cell recognition by tumor-specific
cytotoxic T cells, enhanced tumor antigen presentation by
dendritic cells, up-regulation of maturation of dendritic cells and
IL-12 production, suppression of accumulation and function of
protumorigenic myeloid-derived suppressor cells and regulatory
dendritic cells, and increase of efficacy of anti-tumor vaccination
protocols [22,23,26,27,28,47]. The fact that Pac in low doses does
not exhibit the neurotoxic activities makes new chemomodulation
approaches even more clinically attractive and feasible.
In summary, our data on murine DRG cultures showed that
tubulin-stabilizing agent paclitaxel in high concentrations has a
significant damaging effect on axonal growth and that this effect is
partially mediated through TLR4 pathways. Low concentrations
of Pac are devoid of neuronal toxicity and thus can be safely used
in a chemomodulation mode. Future studies in the field should
reveal dose-dependent neurotropic effects of other microtubule-
binding agents and confirm their effects on neurons in the in-vivo
setting.
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